Hanmi Pharm. Co., Ltd. (KRX:128940)

South Korea flag South Korea · Delayed Price · Currency is KRW
491,500
-3,000 (-0.61%)
Apr 28, 2026, 3:30 PM KST
104.79%
Market Cap 6.23T
Revenue (ttm) 1.55T
Net Income (ttm) 169.55B
Shares Out 12.68M
EPS (ttm) 13,362.00
PE Ratio 36.78
Forward PE 35.37
Dividend 1,250.00 (0.25%)
Ex-Dividend Date Mar 30, 2026
Volume 72,878
Average Volume 81,692
Open 494,000
Previous Close 494,500
Day's Range 486,000 - 497,000
52-Week Range 237,500 - 647,000
Beta 0.62
RSI 44.12
Earnings Date Apr 30, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha... [Read more]

Sector Healthcare
Founded 1973
Employees 2,400
Stock Exchange Korea Stock Exchange
Ticker Symbol 128940
Full Company Profile

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Financial Statements

News

There is no news available yet.